Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.
FORGE NEW CHEMISTRY
Distinct from traditional approaches for ‘hit’ discovery using high throughput screens, the FORGE approach starts with metal-ligand interactions to identify selective metal-binding pharmacophore fragments from our proprietary library. Using bio-inorganic and medicinal chemistry principles, full-length inhibitors are developed using a novel fragment growth strategy incorporating computational and structural biology.
FORGE NEW MEDICINES
Shining a light on a problem from a different direction can reveal undiscovered solutions. At FORGE, we are uniquely discovering compounds that have potential for first-in-class medicines. As an example of this differentiation, our LpxC inhibitor is the first ever non-hydroxamate to demonstrate in vivo efficacy. Additionally, we are discovering new chemical scaffolds for our oncology programs, FG-KDM and FG-IDO, which overcome existing chemical limitations in their respective fields.
WE ARE FORGE
Forge was founded by leading bio-inorganic scientists and industry experts with the vision of creating a significant biotechnology company that couples pioneering metalloprotein technology with rigorous research to create life-saving medicines in areas of high unmet needs.
Zachary Zimmerman, Ph.D.
Chief Executive Officer
David Puerta, Ph.D.
Chief Operating Officer and Vice President of Discovery
Min Teng, Ph.D.
Senior Principal Scientist, Medicinal Chemistry
Konstantin Taganov, Ph.D.
Principal Scientist, Biology
Baskar Nammalwar, Ph.D.
Research Scientist, Synthetic Chemistry
Xiaoming Li, Ph.D.
Principal Scientist, Medicinal Chemistry
Seth Cohen, Ph.D.
Professor of Chemistry, University of California San Diego Click here to learn more
Bob BalteraCEO of Hawkeye Therapeutics and former CEO of Amira Pharmaceuticals
Tom CollPartner at Cooley LLC
Neil Gibson, Ph.D.former CSO of Regulus Therapeutics, Pfizer Oncology, and OSI
John Schmidformer CFO of Auspex and Trius
Steve Worland, Ph.D.CEO of eFFECTOR and former CEO of Anadys
ANTIBIOTIC DRUG DEVELOPMENT TEAM
Karen Joy Shaw, Ph.D.former Trius, Johnson & Johnson, and Schering Plough; led microbiology strategy for Tedizolid
Michael Barbachyn, Ph.D.former Director Antibacterial Chemistry at Pfizer & AstraZeneca; inventor of ZYVOX
Lynn Silver, Ph.D.former Senior Investigator at Merck;
discovered LpxC and developed INVANZ
Robert Bonomo, M.D.Case Western Reserve University,
Professor of Medicine and Microbiology Chief
Brad Spellberg, M.D.Chief Medical Officer, Los Angeles County & University of Southern California Medical Center
Andrew Tomaras, Ph.D.former LpxC program leader at Pfizer
Partners and Investors
Partnering: Forge Therapeutics is keenly interested in partnering with companies on the discovery and development of novel inhibitors targeting metalloproteins. Our strategy is to utilize business development to add programs and build our pipeline. We incorporate a balanced approach of internal and external programs to create a leading portfolio of first-in-class and best-in-class medicines for high unmet medical needs.
Discovering metalloenzyme inhibitors
for certain disease targets.
Investors: Forge Therapeutics raised a seed round in 2015 from friends & family, financial professionals, and angel investors.
Testing Forge antibiotics in infection models.
Testing Forge compounds
in cancer models.
Collaboration to validate ‘drugability’
of Jumonji KDMs
Strategic ‘superbug’ alliance to advance novel class of antibiotics